Your search returned the following 32 documents:

32. Efficacy of antiretroviral therapy switch in HIV-infected patients: A 10-year analysis of the EuResist cohort
    Mark Oette, Eugen Schulter, Michal Rosen-Zvi, Yardena Peres, Maurizio Zazzi, Anders Sonnerborg, Daniel Struck, Andre Altmann, and Rolf Kaiser
    Intervirology 55 (2): 160-166, 2012
    
31. Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project
    Maurizio Zazzi, Francesca Incardona, Michal Rosen-Zvi, Mattia Prosperi, Thomas Lengauer, Andre Altmann, Anders Sonnerborg, Tamar Lavee, Eugen Schülter, and Rolf Kaiser
    Intervirology 55 (2): 123-127, 2012
    
30. A Computational Method for Predicting First-Line Antiretroviral Therapy Success
    Alejandro Pironti, André Altmann, Joachim Büch, and Thomas Lengauer
    In: Abstract Book. 9th Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance, Paphos, Cyprus, 2011, 94 p.
    
29. Learning from past treatments and their outcome improves prediction of In Vivo response to anti-HIV therapy
    Hiroto Saigo, André Altmann, Jasmina Bogojeska, Fabian Müller, Sebastian Nowozin, and Thomas Lengauer
    Statistical Applications in Genetics and Molecular Biology 10 (1): 1-32, 2011
    
    
28. Prediction of Response to Antiretroviral Therapy by Human Experts and by the EuResist Data-Driven Expert System (the EVE study)
    M. Zazzi, R. Kaiser, A. Sönnerborg, D Struck, Andre Altmann, M. Prosperi, M. Rosen-Zvi, A. Petroczi, Y. Peres, E. Schülter, C.A. Boucher, F. Brun-Vezinet, R. Harrigan, L. Morris, M. Obermeier, C.-F. Perno, P. Phanuphak, D Pillay, R.W. Shafer, A.-M. Vandamme, K. Van Laethem, A. Wensing, Thomas Lengauer, and F. Incardona
    HIV Medicine 12 (4): 211-218, 2011
    
27. HIV-1 mutational pathways under multidrug therapy
    Glenn Lawyer, André Altmann, Alex Thielen, Maurizio Zazzi, Anders Sönnerborg, and Thomas Lengauer
    AIDS Research and Therapy 8 (1): 1-13, 2011
    
26. Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
    Mattia C. F. Prosperi, Michal Rosen-Zvi, Andre Altmann, Maurizio Zazzi, Simona Di Giambenedetto, Rolf Kaiser, Eugen Schülter, Daniel Struck, Peter Sloot, David A. van de Vijver, Anne-Mieke Vandamme, and Anders Sönnerborg
    PLoS ONE 5 (10): e13753,1-e13753,8, 2010
    
25. Bioinformatical approaches to ranking of anti-HIV combination therapies and planning of treatment schedules
    André Altmann
    Doctoral dissertation, Universität des Saarlandes, 2010
    
24. Chasing the AIDS Virus
    Thomas Lengauer, André Altmann, Alexander Thielen, and Rolf Kaiser
    Communications of the ACM 53 (3): 66-74, 2010
    
23. Dealing with sparse data in predicting outcomes of HIV combination therapies
    Jasmina Bogojeska, Steffen Bickel, André Altmann, and Thomas Lengauer
    Bioinformatics 26 (17): 2085-2092, 2010
    
    
22. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data
    Andre Altmann, Alejandro Pironti, Juliane Perner, Joachim Büch, and Thomas Lengauer
    In: Abstract Book. 8th European Drug Resistance Workshop, Sorrento, Italy, 2010, 46 p.
    
21. Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
    Hendrik Weisser, André Altmann, Saleta Sierra, Francesca Incardona, Daniel Struck, Anders Sönnerborg, Rolf Kaiser, Maurizio Zazzi, Monika Tschochner, Hauke Walter, and Thomas Lengauer
    PLoSOne 5 (2): e9044,1-e9044,10, 2010
    
20. Permutation importance: an unbiased feature importance measure
    André Altmann, Laura Tolosi, Oliver Sander, and Thomas Lengauer
    Bioinformatics 26 (10): 1340-1347, 2010
    
19. Prediction of Response to Antiretroviral Therapy by Human Experts and by the EuResist Data-Driven Expert System (the EVE Study)
    Maurizio Zazzi, Rolf Kaiser, Anders Sönnerborg, Daniel Struck, Andre Altmann, Mattia C. F. Prosperi, Michal Rosen-Zvi, Andrea Petroczi, Yardena Peres, Eugen Schülter, Charles Boucher, Francoise Brun-Vezinet, Richard Harigan, Lynn Morris, Martin Obermeier, Federico Perno, Robert Shafer, Anne-Mieke Vandamme, Kristel van Laethem, Annemarie Wensing, Thomas Lengauer, and Francesca Incardona
    HIV Medicine Early View: 1-8, 2010
    
18. Advantages of Predicted Phenotypes and Statistical Learning Models in Inferring Virological Response to Antiretroviral Therapy from HIV Genotype
    André Altmann, Tobias Sing, Hans Vermeiren, Bart Winters, Elke Van Craenenbroeck, Koen Van der Borght, Soo-Yon Rhee, Robert W. Shafer, Eugen Schülter, Rolf Kaiser, Yardena Peres, Anders Sönnerborg, W. Jeffrey Fessel, Francesca Incardona, Maurizio Zazzi, Lee Bacheler, Hermann Van Vlijmen, and Thomas Lengauer
    Antiviral Therapy 14 (2): 273-283, 2009
    
17. Bioinformatische Unterstützung der Auswahl von HIV Therapien
    Thomas Lengauer, André Altmann, and Alexander Thielen
    Informatik Spektrum 32 (2): 320-331, 2009
    
16. Estimating evolutionary pathways to 7CXCR4 usage from cross-sectional data
    Alexander Thielen, André Altmann, Jasmina Bogojeska, Rolf Kaiser, and Thomas Lengauer
    In: Abstracts presented at the XVIII International HIV Drug Resistance Workshop : Basic Principles & Clinical Implications, Fort Myers, USA, 2009, A16-A16, paper no. Abstract 14.
    
15. Evolution of raltegravir resistance during therapy
    Nadine Sichtig, Saleta Sierra, Rolf Kaiser, Martin Däumer, Stefan Reuter, Eugen Schülter, André Altmann, Gerd Fätkenheuer, Ulf Dittmer, Herbert Pfister, and Stefan Esser
    Journal of antimicrobial chemotherapy 64 (1): 25-32, 2009
    
14. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment
    Mattia C. F. Prosperi, André Altmann, Michal Rosen-Zvi, Ehud Aharoni, Borgulya Gabor, Bazso Fulop, Anders Sonnerborg, Eugen Schulter, Daniel Struck, Giovanni Ulivi, Anne-Mieke Vandamme, Jurgen Vercauteren, and Maurizio Zazzi
    Antiviral Therapy 14 (3): 433-442, 2009
    
13. Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2pheno-THEO on a Large Clinical Database
    André Altmann, Martin Däumer, Niko Beerenwinkel, Yardena Peres, Eugen Schülter, Joachim Büch, Soo-Yon Rhee, Anders Sönnerborg, W. Jeffrey Fessel, Robert W. Shafer, Maurizio Zazzi, Rolf Kaiser, and Thomas Lengauer
    The Journal of Infectious Diseases 199 (7): 999-1006, 2009
    
12. Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy
    Andre Altmann, Michal Rosen-Zvi, Mattia Prosperi, Ehud Aharoni, Hani Neuvirth, Anders Sönnerborg, Eugen Schülter, Joachim Büch, Daniel Struck, Yardena Peres, Francesca Incardona, Rolf Kaiser, Maurizio Zazzi, and Thomas Lengauer
    PLoS ONE 3 (10): e3470 p., 2008
    
11. Computational analysis of covariation and interactions between HIV-1 reverse transcriptase and Integrase
    Oliver Sander, Andre Altmann, and Thomas Lengauer
    In: Reviews in Antiviral Therapy, Budapest, Hungary, 2008, 113-114
    
10. Improved genotypic prediction of HIV-1 coreceptor usage by incorporating V2 loop sequence variation
    Alexander Thielen, P Richard Harrigan, Andrew J. Low, A Moores, Andre Altmann, Kasia Bozek, Eva Heger, Nadine Sichtig, Rolf Kaiser, and Thomas Lengauer
    In: Antiviral Therapy, Sitges, Spain, 2008, A100 p.
    
9. Relevance of HIV gag cleavage site mutations in failures of protease inhibitor therapies
   Jens Verheyen, Andre Altmann, Elena Knops, Eugen Schülter, Nadine Sichtig, Stefan Reuter, Gerd Fätkenheuer, Herbert Pfister, and Rolf Kaiser
   In: Antiviral Therapy, Sitges, Spain, 2008, A53 p.
   
8. Rtreemix: an R package for estimating evolutionary pathways and genetic progression scores
   Jasmina Bogojeska, Adrian Alexa, André Altmann, Thomas Lengauer, and Jörg Rahnenführer
   Bioinformatics 24 (20): 2391-2392, 2008
   
   
7. Selecting anti-HIV therapies based on a variety of genomic and clinical factors
   Michal Rosen-Zvi, Andre Altmann, Mattia Prosperi, Ehud Aharoni, Hani Neuvirth, Anders Sönnerborg, Eugen Schülter, Daniel Struck, Yardena Peres, Francesca Incardona, Rolf Kaiser, Maurizio Zazzi, and Thomas Lengauer
   In: Proceedings of the 16th Annual International Conference on Intelligent Systems for Molecular Biology (ISMB 2008), Toronto, Canada, 2008, i399-406
   
6. Sustaining lamivudine/emtricitabine, abacavir, zidovudine or atazanavir from a previous treatment shows a clinical benefit
   Michal Rosen-Zvi, Eugen Schülter, Andre Altmann, Saleta Sierra-Aragon, Maurizio Zazzi, Anders Sönnerborg, Mark Oette, Thomas Lengauer, and Rolf Kaiser
   In: Antiviral Therapy, Sitges, Spain, 2008, A86 p.
   
5. The EuResist approach for predicting response to anti HIV-1 therapy
   Andre Altmann, Michal Rosen-Zvi, Mattia Prosperi, Ehud Aharoni, Hani Neuvirth, Eugen Schülter, Joachim Büch, Yardena Peres, Incardona Incardona, Anders Sönnerborg, Rolf Kaiser, Maurizio Zazzi, and Thomas Lengauer
   In: Reviews in Antiviral Therapy, Budapest, Hungary, 2008, 107 p.
   
4. Improved prediction of response to antiretroviral combination therapy using the genetic barrier to drug resistance
   Andre Altmann, Niko Beerenwinkel, Tobias Sing, Igor Savenkov, Martin Däumer, Rolf Kaiser, Soo-Yon Rhee, W Jeffrey Fessel, Robert W Shafer, and Thomas Lengauer
   Antiviral Therapy 12 (2): 169-178, 2007
   
3. Inferring virological response from genotype: with or without predicted phenotypes?
   Andre Altmann, Tobias Sing, Hans Vermeiren, Bart Winters, Elke Van Craenenbroeck, Koen Van der Borght, Soo-Yon Rhee, Robert W Shafer, Eugen Schülter, Rolf Kaiser, Yardena Peres, Anders Sonnerborg, W Jeffrey Fessel, Francesca Incardona, Maurizio Zazzi, Lee Bacheler, Hermann Van Vlijmen, and Thomas Lengauer
   In: Proceedings of the 16th International HIV Drug Resistance Workshop, Barbados, Barbados, 2007, S169 p.
   
2. Validation of geno2pheno and THEO on a large independent clinical dataset
   Andre Altmann, Martin Däumer, Tobias Sing, Niko Beerenwinkel, Hauke Walter, Rolf Kaiser, and Thomas Lengauer
   In: Proceedings of the 5th European HIV Drug Resistance Workshop, Cascais, Portugal, 2007
   
1. EuResist: exploration of multiple modeling techniques for prediction of response to treatment
   Maurizio Zazzi, Ehud Aharoni, Andre Altmann, Fulop Baszó, Penny Bidgood, Gabór Borgulya, J Denholm-Prince, M Fielder, Rolf Kaiser, Carmel Kent, Thomas Lengauer, T Nepusz, Hanni Neuvirth, Yardena Peres, Andrea Petroczi, Mattia Prosperi, L Romano, Michal Rosen-Zvi, Eugen Schülter, Tobias Sing, Andras Sonnerborg, R Thompson, G Ulivi, L Zalány, and Francesca Incardona
   In: Proceedings of the 5th European HIV Drug Resistance Workshop, Cascais, Portugal, 2007